Trial · NCT00464620
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate: Number of Participants With Objective Tumor Response | Up to 24 months | 116 subjects enrolled in the Indolent subtype, however 109 subjects began treatment. 50 patients enrolled in the GIST subtype, however 48 patients were evaluable. This explains the discrepancy between Overall Number of Participants Analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | 6 Month Progression-free Survival Rate of Indolent Sarcomas Treated With Dasatinib | At 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | 6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST) | 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Median Time-to-progression of Subjects With GIST Treated With Dasatinib. | Up to 30 months | months | MEDIAN | |
| SECONDARY | Overall Survival Rates at 2 and 5 Years From Registration of Subjects Treated With Dasatinib. | At 2 and 5 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Median Time-to-progression of Subjects With Indolent Sarcomas Treated With Dasatinib. | Up to 24 months | months | MEDIAN | |
| SECONDARY | 6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype. | At 6 months | The numbers analyzed in one or more rows are different because they are broken up by cohorts. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Median Time-to-progression of Subjects Enrolled in the Aggressive Subtype. | Up to 37 weeks | months | MEDIAN | |
| SECONDARY | Overall Survival Rates at 2 and 5 Years From Registration of Subjects Enrolled in the Aggressive Subtype Treated With Dasatinib. | At 2 and 5 years | The number analyzed in one or more rows differs from overall number because the rows are broken down into cohorts. The counts in the categories will not add up to the number analyzed, because those numbers represent number of participants that have reached overall survival at 2 and 5 years. | participants | NUMBER |
| SECONDARY | Uni-dimensional and Bi-dimensional Tumor Size, Tumor Volumes and Tumor Average Density Determined by Computer-aided Automated Detection in a Subset of Subjects With Tumor Predominately Involving the Lung | Up to 37 weeks | This data was not collected because the imaging software and work station was not obtained. | ||
| SECONDARY | Plasma Level of Dasatinib and Inhibition of SRC and/or Focal Adhesion Kinase (FAK) in Peripheral Blood Mononuclear Cells | 2-4 weeks from start of treatment | Evaluation of blood levels of drug was not performed because there was insufficient activity and the level of activity did not warrant further study. | ||
| SECONDARY | Number of Participants With Tumors With Kinase Expression | Up to 37 weeks | The overall number of participants analyzed demonstrates the number of participants whose tumor samples received. The results illustrate the tissue that was able to generate tissue microarray for SRC and FAK analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Tumors With Mutations in Kinases | Up to 37 weeks | The overall number of participants analyzed demonstrates the number of participants whose tumor samples were received. The results illustrate the tissue that was able to generate tissue microarray for PDGFR analysis. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00464620/outcomes